OncoMatch/Clinical Trials/NCT07069712
A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma
Is NCT07069712 recruiting? Yes, currently enrolling (Sep 2026). This Phase 2 trial studies multiple treatments for gastroesophageal adenocarcinoma.
Treatment: Sonesitatug Vedotin · Rilvegostomig · Trastuzumab Deruxtecan (T-DXd) · Capecitabine · 5-Fluorouracil (5-FU) · FLOT Chemotherapy · Calcium folinate — GEMINI-PeriOp GC study will assess the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity of novel agents or novel combinations as perioperative treatment in participants with locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma who have not received previous treatment for the disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Targeted therapy
Chemotherapy
Other
Cancer type
Gastric Cancer
Esophageal Carcinoma
Biomarker criteria
Required: CLDN18 expression (positive)
Participants who are CLDN18.2-positive in Sub-study 1
Required: HER2 (ERBB2) overexpression (positive)
HER2-positive in Sub-study 2
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: anti-cancer treatment or surgery for current gastric, GEJ, or esophageal cancer
Participants had any prior anti-cancer treatment or surgery for the current gastric, GEJ, or esophageal cancer.
Lab requirements
Blood counts
adequate organ and bone marrow function
Kidney function
adequate organ and bone marrow function
Liver function
adequate organ and bone marrow function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Newark, Delaware
- Research Site · Washington D.C., District of Columbia
- Research Site · Fairway, Kansas
- Research Site · North Shores, Michigan
- Research Site · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07069712 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CLDN18?
Yes, CLDN18 expression is a required biomarker for enrollment.
Does this trial require ERBB2?
Yes, ERBB2 overexpression is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify